Abstract:Background: Genetic mutations play a crucial role in the development and progression of myelodysplastic syndromes (MDS), impacting the immune microenvironment and influencing the choice of treatment regimen, as well as the efficacy and prognosis of patients. The objective of this study was to examine variations in hematological and immunological characteristics associated with common gene mutations in MDS patients and establish a foundation for the precise treatment of MDS. Methods: The hematological, immunological, and other clinical features of 71 recently diagnosed MDS patients from January 1, 2019, to July 31, 2023, were retrospectively analyzed. These patients were categorized based on their gene mutations, and the variances in hematological and immunological characteristics among distinct groups were compared. Results: Hematological variances were observed among different gene mutation groups. Specifically, platelet counts in the splicing factor 3B subunit 1 (SF3B1) mutation group were notably higher compared to the wild-type group (p = 0.009). Conversely, in the additional sex combs like 1 (ASXL1) mutation groups, monocyte ratios were significantly elevated in comparison to the wild-type group (p = 0.046), and in the ten-eleven translocation 2 (TET2) mutation group, lymphocyte ratios were significantly lower (p = 0.022). Additionally, the leukocyte (p = 0.005), neutrophil ratio (p = 0.002), and lymphocyte ratio (p = 0.001) were significantly higher in the Runt-related transcription factor 1 (RUNX1) mutation group. Regarding immunological distinctions, the Natural Killer (NK) cell ratio demonstrated a significant increase in the SF3B1 mutation group (p = 0.005). Moreover, the TET2 mutation group exhibited a significantly higher Interleukin-8 (IL-8) level (p = 0.017). In contrast, the U2 small nuclear RNA auxiliary factor 1 (U2AF1) group displayed significantly lower levels of IL-1β (p = 0.033), IL-10 (p = 0.033), and Tumour Necrosis Factor-α (TNF-α) (p = 0.009). Conclusion: Distinct variations exist in the immune microenvironment of MDS associated with different genetic mutations. Further studies are imperative to delve into the underlying mechanisms that drive these differences.

Gene Mutations and the Phenotype of BCR/ABL-negative Myeloproliferative Neoplasms

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Impact of TET2, SRSF2, ASXL1 and SETBP1 Mutations on Survival of Patients with Chronic Myelomonocytic Leukemia.

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Karyotypic Analysis and Prognosis for 41 Patients with Chronic Myelomonocytic Leukemia

Effects of JAK2 V556F Mutation on the JAK2's Activity, Structural Stability and the Transformation of Ba/F3 Cells.

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms

Research of gene mutation in acute myeloid leukemia: development and prospect

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.

Abstract B034: Order-of-mutation effects on cancer progression: Models for myeloproliferative neoplasm

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase

Progress of CALR Gene Mutation in Myeloproliferative Neoplasm

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Advances in molecular evaluation of myeloproliferative neoplasms

[Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)

Genetic landscape of chronic myeloid leukemia

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

Analyzing Differences in Hematological and Immunological Characteristics Related to Common Gene Mutations in Myelodysplastic Syndromes